TY - JOUR
T1 - Regulation of prolactin secretion by dopamine and vasoactive intestinal peptide at the level of the pituitary in the turkey
AU - Youngren, Orlan M.
AU - Chaiseha, Yupaporn
AU - Elhalawani, M E
PY - 1998/11/30
Y1 - 1998/11/30
N2 - This study investigated the capability of dopamine (DA) to prevent avian prolactin (PRL) secretion by antagonizing the PRL-releasing factor, vasoactive intestinal peptide (VIP), at the level of the pituitary. To test this hypothesis, combined intracranial and intrapituitary infusions of DA, DA agonists, and VIP, plus electrical stimulation of the medial preoptic area (ES/POM), were used to characterize the actions of DA on PRL secretion in anesthetized laying turkey hens. Infused into the third ventricle at the rate of 10 nmol/min, DA induced a 2.8-fold increase in circulating PRL levels (63.8 ± 15.1 to 181.3 ± 44.3 ng/ml, p < 0.05), similar to the 3.1-fold PRL increase induced by ES/POM (65 ± 10.3 to 199.1 ± 57.3 ng/ml, p < 0.05). Infused into the anterior pituitary at the rate of 15 ng/min, VIP induced a 2.2-fold increase in PRL (78.6 ± 22.9 to 173.6 ± 39.5 ng/ml, p < 0.05). When DA (10 nmol/min) was infused into the anterior pituitary it completely blocked both ES/POM- and VIP-induced PRL secretion. The D2 DA receptor agonist R-(-)-Propylnorapomorphine HCl inhibited VIP-induced PRL secretion at the level of the anterior pituitary, allowing only an insignificant rise in PRL (54.8 ± 14.3 to 73.9 ± 21.6 ng/ml, p > 0.05), while the D1 DA receptor agonist (±)-SKF-38393 HCl failed to prevent VIP-induced PRL release, allowing PRL to rise 2.5-fold (49.1 ± 10.8 to 121.0 ± 34.8 ng/ml, p < 0.05). Pituitary infusion of DA, DA agonists or vehicle alone caused no change in PRL levels. The data showed that DA prevented avian PRL secretion by blocking the action of VIP at the level of the anterior pituitary. DA effected this blockade of PRL via D2 DA receptors residing within the anterior pituitary. The data also suggested that there were no stimulatory D1 DA receptors related to PRL secretion in the avian anterior pituitary.
AB - This study investigated the capability of dopamine (DA) to prevent avian prolactin (PRL) secretion by antagonizing the PRL-releasing factor, vasoactive intestinal peptide (VIP), at the level of the pituitary. To test this hypothesis, combined intracranial and intrapituitary infusions of DA, DA agonists, and VIP, plus electrical stimulation of the medial preoptic area (ES/POM), were used to characterize the actions of DA on PRL secretion in anesthetized laying turkey hens. Infused into the third ventricle at the rate of 10 nmol/min, DA induced a 2.8-fold increase in circulating PRL levels (63.8 ± 15.1 to 181.3 ± 44.3 ng/ml, p < 0.05), similar to the 3.1-fold PRL increase induced by ES/POM (65 ± 10.3 to 199.1 ± 57.3 ng/ml, p < 0.05). Infused into the anterior pituitary at the rate of 15 ng/min, VIP induced a 2.2-fold increase in PRL (78.6 ± 22.9 to 173.6 ± 39.5 ng/ml, p < 0.05). When DA (10 nmol/min) was infused into the anterior pituitary it completely blocked both ES/POM- and VIP-induced PRL secretion. The D2 DA receptor agonist R-(-)-Propylnorapomorphine HCl inhibited VIP-induced PRL secretion at the level of the anterior pituitary, allowing only an insignificant rise in PRL (54.8 ± 14.3 to 73.9 ± 21.6 ng/ml, p > 0.05), while the D1 DA receptor agonist (±)-SKF-38393 HCl failed to prevent VIP-induced PRL release, allowing PRL to rise 2.5-fold (49.1 ± 10.8 to 121.0 ± 34.8 ng/ml, p < 0.05). Pituitary infusion of DA, DA agonists or vehicle alone caused no change in PRL levels. The data showed that DA prevented avian PRL secretion by blocking the action of VIP at the level of the anterior pituitary. DA effected this blockade of PRL via D2 DA receptors residing within the anterior pituitary. The data also suggested that there were no stimulatory D1 DA receptors related to PRL secretion in the avian anterior pituitary.
KW - Birds
KW - Catecholamine receptors
KW - Catecholamines
KW - Prolactin
KW - Vasoactive intestinal peptide
UR - http://www.scopus.com/inward/record.url?scp=0031729293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031729293&partnerID=8YFLogxK
U2 - 10.1159/000054380
DO - 10.1159/000054380
M3 - Article
C2 - 9822799
AN - SCOPUS:0031729293
SN - 0028-3835
VL - 68
SP - 319
EP - 325
JO - Neuroendocrinology
JF - Neuroendocrinology
IS - 5
ER -